Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

By Keizer Ron  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1519-1530

Springer Publishing Company

Access to resources Recommend Favorite

Design Issues in Dose-Finding Phase I Trials for Combinations of Two Agents

By Fan Shenghua Kelly  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 3, 2009-05 ,pp. : 509-523

Taylor & Francis Ltd

Access to resources Recommend Favorite

An Adaptive Design for Phase II Non-Oncology Dose Selection Clinical Trials

By Su Zheng  

Clinical Drug Investigation, Vol. 30, Iss. 6, 2010-06 ,pp. : 397-403

Adis International

Access to resources Recommend Favorite

Selecting Promising Treatments in Randomized Phase II Cancer Trials with an Active Control

By Cheung Ying Kuen  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 3, 2009-05 ,pp. : 494-508

Taylor & Francis Ltd

Access to resources Recommend Favorite

SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group

By Wong R.   Baetz T.   Krahn M.   Biagi J.   Wainman N.   Eisenhauer E.  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 347-351

Springer Publishing Company

Access to resources Recommend Favorite